
The Clorox Company


Three months ended Mar. 31, 2025
Percentage change versus the year-ago period
	Reported (GAAP) Net Sales Growth/ (Decrease)	Reported Volume	Acquisitions & Divestitures (1)	Foreign Exchange Impact	Price Mix and Other (2)	Organic Sales Growth/ (Decrease) (Non-GAAP) (3)	Organic Volume (4)
Health and Wellness	3%	7%	—%	—%	(4)%	3%	7%
Household	(11)	(9)	—	—	(2)	(11)	(9)
Lifestyle	(3)	(2)	—	—	(1)	(3)	(2)
International (4)	(15)	(15)	(14)	(3)	3	2	1
Total Company (4)(5)	(8)%	(7)%	(5)%	(1)%	—%	(2)%	—%


Nine months ended Mar. 31, 2025
Percentage change versus the year-ago period
	Reported (GAAP) Net Sales Growth/ (Decrease)	Reported Volume	Acquisitions & Divestitures (1)	Foreign Exchange Impact	Price Mix and Other (2)	Organic Sales Growth/ (Decrease) (Non-GAAP) (3)	Organic Volume (4)
Health and Wellness	7%	9%	—%	—%	(2)%	7%	9%
Household	1	2	—	—	(1)	1	2
Lifestyle	2	3	—	—	(1)	2	3
International (4)	(11)	(11)	(14)	(3)	3	6	6
Total Company (4)(5)	(1)%	(1)%	(5)%	—%	—%	4%	5%

(1)The divestiture impact is calculated as net sales from the Argentina and Better Health Vitamins, Minerals and Supplements (VMS) businesses after the respective sale dates in the three and nine month year-ago periods.

(2)This represents the net impact on net sales growth / (decrease) from pricing actions, mix, trade promotion spending, mix from acquisitions and divestitures and other factors. In the three months ended Mar. 31, 2025, the impact from divestiture mix was 2% for both International and Total Company. In the nine months ended Mar. 31, 2025, the impact from divestiture mix was 3% and 1% for International and Total Company, respectively.

(3)Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of any acquisitions and divestitures and foreign exchange rate changes. See below for reconciliation of organic sales growth / (decrease) to net sales growth / (decrease), the most directly comparable GAAP financial information.

Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the company was operating throughout the relevant periods, and the impact of foreign exchange rate changes, which are out of the control of the company and management. However, organic sales growth / (decrease) may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded.

(4)Organic volume represents volume excluding the effect of any acquisitions and divestitures. In the three months ended Mar. 31, 2025, the volume impact of divestitures was (16%) and (7%) for International and Total Company, respectively. In the nine months ended Mar. 31, 2025, the volume impact of divestitures was (17%) and (6%) for International and Total Company, respectively.

(5)Total Company includes Corporate and Other. Corporate and Other includes the results of the Better Health VMS business through the date of divestiture.


The Clorox Company

The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:


	Three months ended Mar. 31, 2025
	Percentage change versus the year-ago period
	Health and Wellness	Household	Lifestyle	International	Total Company (1)
Net sales growth / (decrease) (GAAP)	3%	(11)%	(3)%	(15)%	(8)%
Add: Foreign exchange	—	—	—	3	1
Add/(Subtract): Divestitures/acquisitions (2)	—	—	—	14	5
Organic sales growth / (decrease) (non-GAAP)	3%	(11)%	(3)%	2%	(2)%


	Nine months ended Mar. 31, 2025
	Percentage change versus the year-ago period
	Health and Wellness	Household	Lifestyle	International	Total Company (1)
Net sales growth / (decrease) (GAAP)	7%	1%	2%	(11)%	(1)%
Add: Foreign Exchange	—	—	—	3	—
Add/(Subtract): Divestitures/Acquisitions (2)	—	—	—	14	5
Organic sales growth / (decrease) (non-GAAP)	7%	1%	2%	6%	4%

(1)Total Company includes Corporate and Other. Corporate and Other includes the results of the Better Health VMS business through the date of divestiture.

(2)The divestiture impact is calculated as net sales from the Argentina and Better Health VMS businesses after the respective sale dates in the three and nine month year-ago periods.


The Clorox Company

Supplemental Unaudited Condensed Information – Gross Margin Drivers

The table below provides details on the drivers of gross margin change versus the year-ago period.

Driver

Gross Margin Change vs. Prior Year (basis points)

FY24

FY25

Cost Savings

+220

+170

+140

+170

+180

+240

+170

Price Changes

+470

+380

+420

+10

+300

+20

+10

Market Movement (commodities)

-20

+60

+10

+20

-20

-40

Manufacturing & Logistics

+10

-210

+190

+60

-10

-30

+40

All other (1) (2) (3) (4) (5)

-430

+170

-290

-50

-190

+470

-100

+60

Change vs prior year

+240

+730

+40

+380

+360

+740

+30

+240

Gross Margin (%)

38.4%

43.5%

42.2%

46.5%

43.0%

45.8%

43.8%

44.6%

(1)In Q1 of fiscal year 2024, "All other" includes the impact from lower shipment volumes and mix and assortment.

(2)In Q2 of fiscal year 2024, "All other" includes the positive impact from higher shipment volumes and the negative impact from foreign exchange.

(3)In Q3 of fiscal year 2024, "All other" includes the negative impact from foreign exchange and higher trade promotion spending.

(4)In Q1 of fiscal year 2025, "All other" includes the positive impact from higher shipment volumes.

(5)In Q2 of fiscal year 2025, "All other" includes the negative impact from lower shipment volumes.


The Clorox Company

Supplemental Unaudited Condensed Information – Cash Flow

For the quarter ended Mar. 31, 2025

Capital expenditures for the third quarter were $53 million versus $55 million in the year-ago quarter.

Depreciation and amortization expense for the third quarter was $55 million versus $58 million in the year-ago quarter.

Net cash provided by operations in the third quarter was $286 million, or 17.1% of net sales.

Supplemental Unaudited Condensed Information – Free Cash Flow

Fiscal Year Free Cash Flow Reconciliation

Dollars in millions and percentages based on rounded numbers


	Q3 Fiscal YTD 2025	Q3 Fiscal YTD 2024
Net cash provided by operations – GAAP	$687	$355
Less: Capital expenditures	$145	$131
Free cash flow – non-GAAP (1)	$542	$224
Free cash flow as a percentage of net sales – non-GAAP (1)	10.6%	4.3%
Net sales	$5,116	$5,190

(1)In accordance with the SEC's Regulation G, this schedule provides the definition of certain non-GAAP measures and the reconciliation to the most closely related GAAP measure. Management uses free cash flow and free cash flow as a percentage of net sales to help assess the cash generation ability of the business and funds available for investing activities, such as acquisitions and divestitures, investing in the business to drive growth, and financing activities, including debt payments, dividend payments and stock repurchases. Free cash flow does not represent cash available only for discretionary expenditures since the Company has mandatory debt service requirements and other contractual and non-discretionary expenditures. In addition, free cash flow may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures and should be read in connection with the company’s consolidated financial statements presented in accordance with GAAP.


The Clorox Company

Supplemental Unaudited Reconciliation of Earnings (Losses) Before Income Taxes to EBIT(1)(3) and Adjusted EBIT(2)(3)

Dollars in millions and percentages based on rounded numbers


	FY 2024						FY 2025

	Q1	Q2	Q3		Q4	FY	Q1	Q2	Q3
	9/30/2023	12/31/2023	3/31/2024		6/30/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Earnings (losses) before income taxes	$29	$136	($42)		$275	$398	$177	$237	$254
Interest income	(10)	(7)	(4)		(2)	(23)	(3)	(2)	(2)
Interest expense	21	26	22		21	90	21	22	23
EBIT (1)(3)	$40	$155	($24)		$294	$465	$195	$257	$275
EBIT margin (1)(3)	2.9%	7.8%	-1.3	%	15.4%	6.6%	11.1%	15.2%	16.5%
Loss on divestiture (4)	—	—	240		—	240	118	—	—
Pension settlement charge (5)	—	171	—		—	171	—	—	—
Cyberattack costs, net of insurance recoveries (6)	24	25	8		(28)	29	(10)	(25)	(35)

Streamlined operating model (7)	—	3	10		19	32	—	—	—
Digital capabilities and productivity enhancements investment (8)	27	32	26		23	108	29	26	26
Adjusted EBIT – non-GAAP (2)(3)	$91	$386	$260		$308	$1,045	$332	$258	$266
Adjusted EBIT margin (2)(3)	6.6%	19.4%	14.3%		16.2%	14.7%	18.8%	15.3%	15.9%
Net sales	$1,386	$1,990	$1,814		$1,903	$7,093	$1,762	$1,686	$1,668

(1)EBIT (a non-GAAP measure) represents earnings (losses) before income taxes (a GAAP measure), excluding interest income and interest expense, as reported above. EBIT margin is the ratio of EBIT to net sales.

(2)Adjusted EBIT (a non-GAAP measure) represents earnings (losses) before income taxes (a GAAP measure), excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items as reported above). Adjusted EBIT margin is the ratio of adjusted EBIT to net sales. Refer to the Non-GAAP Financial Information within the earnings release for further discussion on the adjustments presented.

(3)In accordance with the SEC's Regulation G, this schedule provides the definition of certain non-GAAP measures and the reconciliation to the most closely related GAAP measure. Management believes the presentation of EBIT, EBIT margin, adjusted EBIT and adjusted EBIT margin provides useful additional information to investors about trends in the company's operations and is useful for comparability of performance over time. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP financial measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read in connection with the company’s consolidated financial statements presented in accordance with GAAP.

(4)Represents losses related to the divestitures of the Argentina and Better Health VMS businesses.

(5)Represents costs related to the settlement of the domestic qualified pension plan.

(6)Reflects incremental costs, net of insurance recoveries, related to the cyberattack. These costs related primarily to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs from the resulting disruption to the company's business operations.

(7)Reflects the restructuring and related implementation costs, net incurred by the company as part of the streamlined operating model. These expenses were primarily attributable to employee-related costs, as well as implementation and other associated costs.

(8)Reflects the operating expenses incurred by the company related to its digital capabilities and productivity enhancements investment. The majority of these expenses relate to external consulting fees. The remaining expenses relate to internal IT project management and supporting personnel costs and other costs.


The Clorox Company

Supplemental Unaudited Reconciliation of Adjusted Earnings (Losses) per Share (8)(10) and Adjusted Effective Tax Rate (9)(10)


(Dollars in millions except per share data)
		Diluted earnings (losses) per share					Effective tax rate
		Three months ended					Three months ended
		3/31/2025		3/31/2024		% Change	3/31/2025	3/31/2024
	As reported (GAAP)	$	1.50	$	(0.41)	466%	24.8%	(18.6)%
	Loss on divestiture (1) (2)	—		1.85			—	26.8%

	Cyberattack costs, net of insurance recoveries (3)	(0.21)		0.05			0.1%	0.5%
	Streamlined operating model (4)	—		0.06			—	0.6%
	Digital capabilities and productivity enhancements investment (5)	0.16		0.16			(0.1)%	1.8%
	As adjusted (Non-GAAP) (8)(9)(10)	$	1.45	$	1.71	(15)%	24.8%	11.1%

		Diluted earnings (losses) per share					Effective tax rate
		Nine months ended					Nine months ended
		3/31/2025		3/31/2024		% Change	3/31/2025	3/31/2024
	As reported (GAAP)	$	3.84	$	0.52	638%	26.9%	41.9%
	Loss on divestiture (1)	0.94		1.85			(4.0)%	(25.3)	%
	Pension settlement charge (6)	—		1.04			—	1.3	%
	Cyberattack costs, net of insurance recoveries (3)	(0.42)		0.35			(0.1)%	0.6%
	Streamlined operating model (4)	—		0.08			—	0.2%
	Digital capabilities and productivity enhancements investment (5)	0.50		0.52			0.1%	1.4%
	As adjusted (Non-GAAP) (8)(9)(10)	$	4.86	$	4.36	11%	22.9%	20.1%

(1)During the three and nine months ended Mar. 31, 2024, the company incurred approximately $240 ($231 after tax) of costs related to the divestiture of the Argentina business. During the nine months ended Mar. 31, 2025, the company incurred an after tax charge of $118 related to the divestiture of the Better Health VMS business.

(2)Includes the dilution impact of the difference between the diluted weighted-average shares used in calculating the diluted (losses) per share, as reported to the diluted weighted-average shares used in calculating the non-GAAP diluted earnings per share, as adjusted (124,892 shares).

(3)During the three and nine months ended Mar. 31, 2025, the company recognized approximately $35 ($26 after tax) and $70 ($53 after tax), respectively, of insurance recoveries related to the August 2023 cyberattack. During the three and nine months ended Mar. 31, 2024, the company incurred approximately $8 ($6 after tax) and $57 ($43 after tax) of costs related to the cyberattack. Refer to the Non-GAAP Financial Information within the earnings release for further discussion.

(4)During the three and nine months ended Mar. 31, 2024, the company incurred approximately $10 ($7 after tax) and $13 ($10 after tax), respectively, of restructuring and related costs, net related to implementation of the streamlined operating model.

(5)During the three and nine months ended Mar. 31, 2025, the company incurred approximately $26 ($20 after tax) and $81 ($62 after tax), respectively, and during the three and nine months ended Mar. 31, 2024, the company incurred approximately $26 ($20 after tax) and $85 ($64 after tax), respectively, of operating expenses related to its digital capabilities and productivity enhancements investment. Refer to the Non-GAAP Financial Information within the earnings release for further discussion.

(6)During the nine months ended Mar. 31, 2024, the company incurred approximately $171 ($130 after tax) of costs related to the settlement of the domestic qualified pension plan.


The Clorox Company


	Full year 2025 outlook (estimated range)
	Diluted earnings per share				Effective tax rate
	Low		High		Estimate
As estimated (GAAP)	$	5.73	$	6.13	26%
Loss on divestiture	0.94		0.94		(3)%

Cyberattack costs, net of insurance recoveries	(0.42)		(0.42)		—


Digital capabilities and productivity enhancements investment (7)	0.70		0.70		—%
As adjusted (Non-GAAP) (8)(9)(10)	$	6.95	$	7.35	23%

(7)In fiscal year 2025, the company expects to incur approximately $105-$115 ($80-$87 after tax) of operating expenses related to its digital capabilities and productivity enhancements investment.

(8)Adjusted EPS is defined as diluted earnings (losses) per share that excludes or has otherwise been adjusted for significant items that are nonrecurring or unusual. The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

(9)Adjusted ETR is defined as the effective tax rate that excludes or that has otherwise been adjusted for significant items that are nonrecurring or unusual.

(10)Adjusted EPS and adjusted ETR are supplemental information that management uses to help evaluate the company's historical and prospective financial performance on a consistent basis over time. Management believes that by adjusting for certain items affecting comparability of performance over time, such as the pension settlement charge, incremental costs and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures, and other nonrecurring or unusual items, investors and management are able to gain additional insight into the company's underlying operating performance on a consistent basis over time. However, adjusted EPS and adjusted ETR may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments. Refer to the Non-GAAP Financial Information within the earnings release for further discussion on the adjustments presented.

CLOROX CO /DE/ 8-K